Importantly, we find that DLK1 is a key driver of chemoresistance in ACC through regulation of NOTCH1 signaling and the drug efflux protein ABCB1 (MDR1, P-glycoprotein), thereby demonstrating an important biological function for this new immunotherapeutic target. The gene discussed is DLK1; the disease is adrenal cortex carcinoma.